Antares 2Q loss widens on R&D expenses
14:36 EDT 8 Aug 2012 | Advantage Business Media
Shares of Antares Pharma Inc. fell Wednesday after the company said its loss widened as it ramped up research spending on its injectable rheumatoid arthritis drug Vibex.The company reported a second-quarter loss of $2.8 million, or 3 cents per share..
Original Article: Antares 2Q loss widens on R&D expenses
More From BioPortfolio on "Antares 2Q loss widens on R&D expenses"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
